Charles Cherington - 24 Sep 2024 Form 4/A - Amendment Insider Report for Ernexa Therapeutics Inc. (ERNA)

Role
10%+ Owner
Signature
/s/ Charles Cherington
Issuer symbol
ERNA
Transactions as of
24 Sep 2024
Net transactions value
-$6,540,000
Form type
4/A - Amendment
Filing time
07 May 2025, 11:48:22 UTC
Date Of Original Report
05 Nov 2024
Previous filing
05 Nov 2024
Next filing
04 Apr 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cherington Charles 10%+ Owner 200 BERKLEY STREET, 26TH FLOOR, BOSTON /s/ Charles Cherington 07 May 2025 0001448698

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERNA Common Stock Purchase +261,756 +47% 818,221 24 Sep 2024 Direct F1, F2, F3, F5, F6
transaction ERNA Common Stock Purchase +4,768,783 +583% 5,587,004 24 Sep 2024 Direct F1, F2, F4, F5, F7
transaction ERNA Common Stock Purchase +1,237,762 +22% 6,824,766 24 Sep 2024 Direct F1, F2, F3, F5, F8
transaction ERNA Common Stock Purchase +5,420,823 +79% 12,245,589 24 Sep 2024 Direct F1, F2, F4, F5, F9
transaction ERNA Common Stock Purchase +1,562,988 +13% 13,808,577 24 Sep 2024 Direct F1, F2, F3, F5, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA 12.0% Senior Convertible Notes due December 12, 2028 Sale $3,000,000 0 24 Sep 2024 Common Stock 3,125,976 $1.92 Direct F1, F2, F4, F5
transaction ERNA 6.0% Senior Convertible Promissory Notes due 2028 Sale $3,540,000 0 24 Sep 2024 Common Stock 1,237,762 $2.86 Direct F1, F2, F4, F5
transaction ERNA Warrants (right to buy) Sale -523,512 -100% 0 24 Sep 2024 Common Stock 523,512 $1.43 Direct F1, F2, F3, F5
transaction ERNA Warrants (right to buy) Sale -2,475,524 -100% 0 24 Sep 2024 Common Stock 2,475,524 $1.43 Direct F1, F2, F3, F5
transaction ERNA Warrants (right to buy) Sale -3,125,976 -100% 0 24 Sep 2024 Common Stock 3,125,976 $1.43 Direct F1, F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below.
F2 Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements.
F3 The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange").
F4 The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions").
F5 Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024.
F6 Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of June 2, 2028.
F7 Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 6.0% Senior Convertible Promissory Notes due 2028 in the aggregate principal amount of $3,300,000 plus applicable interest.
F8 Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of July 14, 2028.
F9 Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 12.0% Senior Convertible Notes due December 12, 2028 in the aggregate principal amount of $3,000,000 plus applicable interest.
F10 Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of December 15, 2028.